Does Ozempic Cause Stomach Paralysis?
Ozempic (semaglutide) can cause severe gastrointestinal side effects, including cases of gastroparesis—delayed stomach emptying sometimes called stomach paralysis.[1] The FDA label warns of this risk, with symptoms like nausea, vomiting, and abdominal pain persisting even after stopping the drug in some patients.[2]
What Is Gastroparesis and How Does Ozempic Link to It?
Gastroparesis is a condition where the stomach muscles fail to empty food properly, leading to bloating, pain, and malnutrition risks. Ozempic slows gastric emptying as part of its mechanism to control blood sugar and appetite in type 2 diabetes.[3] While this is intentional for short-term effects, prolonged use has led to confirmed gastroparesis diagnoses. A 2023 study in JAMA found higher rates of gastroparesis among semaglutide users compared to similar drugs like liraglutide.[4]
How Common Is This Side Effect?
Gastroparesis occurs in less than 1% of Ozempic users based on clinical trials, but post-marketing reports show hundreds of cases.[5] The FDA added a warning in 2023 after reviewing adverse event data. Real-world lawsuits claim over 10,000 reports of severe stomach issues, some requiring hospitalization or feeding tubes.[6]
What Do Patients Report Happening?
Users describe constant vomiting of undigested food, inability to eat solids, rapid weight loss beyond intended amounts, and pain lasting months. Some cases resolve after discontinuation, but others become permanent, with one analysis showing 40% of affected patients still symptomatic after a year.[7]
Can It Happen with Other GLP-1 Drugs Like Wegovy or Mounjaro?
Yes, similar risks apply to related drugs. Wegovy (higher-dose semaglutide) and tirzepatide (Mounjaro/Zepbound) share the gastric-slowing mechanism and carry identical FDA warnings.[8] Head-to-head data shows no major differences in GI severe events.[4]
What Does the FDA and Novo Nordisk Say?
The FDA requires gastroparesis warnings on all GLP-1 labels and is monitoring long-term data.[2] Novo Nordisk states most cases are mild and reversible, advising doctors to screen patients with prior GI issues.[9] Ongoing lawsuits challenge claims of underreported risks.
Who Is Most at Risk and What Precautions Exist?
Higher risk for those with diabetes-related nerve damage, prior stomach surgery, or using the drug off-label for weight loss at high doses. Doctors recommend starting low, monitoring symptoms, and stopping if severe issues arise. No specific test predicts it, but endoscopy confirms diagnosis.[10]
Are There Ongoing Studies or Legal Actions?
Clinical trials like STEP and SURMOUNT track long-term GI safety, with interim data showing elevated but manageable risks.[11] Over 100 lawsuits allege Novo Nordisk and Eli Lilly downplayed dangers, seeking damages for permanent injuries.[12]
[1]: FDA Ozempic Label
[2]: FDA Drug Safety Communication
[3]: NEJM Semaglutide Mechanism
[4]: JAMA Gastroparesis Study
[5]: ClinicalTrials.gov Ozempic Data
[6]: USPSTF Adverse Event Reports
[7]: Gastroenterology Journal Case Series
[8]: FDA Wegovy/Mounjaro Labels
[9]: Novo Nordisk Safety Statement
[10]: ACG Gastroparesis Guidelines
[11]: NEJM STEP Trials
[12]: Reuters GLP-1 Litigation Tracker